5 years ago

Theolytics Raises $6.8 Million for Cancer-Fighting Viral Therapy

  • Theolytics, an Oxford, England-based biotech company focused on utilizing viruses to combat cancer, has secured $6.8 million in Series A funding

  • The round was co-led by Epidarex Capital and Taiho Ventures LLC, with participation from existing investor Oxford Sciences Innovation (OSI)

  • The funding will be used to advance Theolytics' pipeline of candidates toward human clinical trials

  • The company aims to revolutionize oncolytic viral therapy through its phenotypic screening platform, discovering and developing highly efficacious and targeted treatment options.

      • ProblemHealthcare

      "Cancer is a leading cause of death worldwide, and current treatments can have significant side effects. There is a need for new and more effective therapies to combat cancer."

      Solution

      "Theolytics is developing a new type of cancer treatment using oncolytic viruses, which are viruses that specifically target and kill cancer cells. The company's platform uses phenotypic screening to identify and develop highly effective and targeted oncolytic viruses that can be delivered intravenously and tailored to specific cancer patient populations."

      Covered on